Longevity big-hitters join our current investment round

Some news of our own: Key investors join the First Longevity funding round.

Among those participating in this second stage funding for First Longevity are Juvenescence Chairman, Jim Mellon, and Bruce Barclay, a member of the Board of Trustees at the Buck Institute.

Longevity.Technology: Today we’re pleased to announce a further six-figure investment in our current funding round for our parent company First Longevity. We are now putting our new investors’ cash to work whilst still keeping our (EIS) funding round open: click here for further info.


 

“I’m very glad to support First Longevity with its large and impressive network within the longevity sector, and look forward to supporting them as they help drive growth in the sector.”

 


 

Bruce Barclay is a New Zealand/British investor, entrepreneur and philanthropist based in Switzerland. Over the course of his varied career, he has worked in a large multinational computing company, a leading venture capital-backed high tech startup in machine vision, robotics and artificial intelligence in Silicon Valley and Oxford, in corporate finance and investment banking in London, and, most recently, at one of the world’s largest and most successful Private Equity Groups, Advent International, where he served as Senior Partner.

“There have been a number of hugely significant technological advances in recent years that are now allowing a deep understanding of why people age and how to “make aging optional”, Barclay told us. “As the technologies refine, this is increasing both innovation and deal activity in the longevity sector, I’m very glad to support First Longevity with its large and impressive network within the longevity sector, and look forward to supporting them as they help drive growth in the sector.”

 


 

“I think they have a unique opportunity to combine editorial skills with investor insights and build a strong business that will bring together growing numbers of longevity investors and entrepreneurs.”

 


 

Jim Mellon needs little introduction to those in the Longevity field. Jim is Chairman of Juvenescence and a British entrepreneur, philanthropist and investor with interests in several industries. He began his investment career in Asia and the US, where he worked for two fund management companies, GT Management and Thornton & Co. He established his own business in 1991, which today has two components: a listed fund management company, Charlemagne Capital Limited and an Asian investment group, Regent Pacific Group Limited.

“Phil and his team have rapidly created a leading media title focused on longevity and that’s good for everyone in this exciting field,” Mellon commented earlier this week. “I think they have a unique opportunity to combine editorial skills with investor insights and build a strong business that will bring together growing numbers of longevity investors and entrepreneurs.”

 

First Longevity Ltd has been formed to capitalise on the growing Longevity opportunity. This news platform launched in September 2019 and delivers daily news and insights to a growing international audience of investors, start-ups, academics and consumers. The next stage of our plan is a digital equity fundraising platform, Crowd Longevity, which will present pre-screened Longevity tech opportunities to our growing investor community.

We earlier announced the appointment of our Advisory Panel of leading experts from Longevity science and investment: the Board and the Advisory Panel will support the development of unique media content, while reviewing the scientific, technical and investment potential of companies presented to equity investors.

Thanks to you for your ongoing interest and advocacy!

Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of Crowd Longevity a digital investment platform for international investors and Longevity start-ups launching in 2020.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Latest articles

Big Brother approach to accelerate preclinical studies

Tracked.bio develops AI computer vision system that tracks flies and mice to reduce man-hours and increase data collected in Longevity studies. A Danish start-up aims...

Deliver us from aging – the Quicksilver method

Bigger certainly doesn't mean better when it comes to Quicksilver's nutraceutical delivery methods. The COVID-19 pandemic has caused an upturn in the supplements industry; from...

Astellas to acquire iota Biosciences

Following an R&D collaboration that began last year, Japanese pharma Astellas has announced it will acquire bioelectronics firm iota in $304m deal. Last year's R&D...

OneSkin launches topical senetherapeutic skin treatment

Extending skinspan with non-invasive senetherapeutic proprietary peptide. OneSkin is a Longevity company on a mission to transform the way we think about skin. Today the...